Medistim ASA (0OCD) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning everyone and welcome to the presentation of Medistim's third quarter results. So my name is Kari Krogstad and I have my CFO Thomas Jakobsen with me and we will take you through the results. Before entering into the highlights, I would like to remind ourselves on our track record and our commitment to deliver profitable growth consistently over time. And as these graphs are describing, that is, I promise we have delivered on. So let's look into the highlights for the third quarter. And after a record start of the year with the first half providing records both for sales and revenues, I'm very happy to present our best third quarter ever for both sales and revenues or operating profits. We can see that we are delivering 166.8 million NOX in revenues. That's a 25.7% growth. And EBIT also growing very nicely, ending at 40.6 million, 27.1% growth. We can see that we have very little currency effect this quarter. That means that the total sales is almost the same, 25.9%. And looking at the sales of our own products, we see that that is at almost 30 percent. So a very, very nice contribution from our own products this quarter. And Americas is continuing to take the lead here up 35.7 percent. And of the 34 million of growth this quarter, Americas are actually delivering 21.5, so 63% of the total nominal value here is coming from Americas, just highlighting the importance of this region for Medicin's growth. Asia Pacific also delivering very nicely, 194% growth. And the only disappointment here this quarter is that EMEA is a bit down. It is the European part that is showing a decline this quarter, while the Middle East Africa section of it is actually growing. And we will get back to more details into what's happening this quarter in EMEA. The third-party product...